Less Vertebral Bone Mass after Treatment with Macitentan in Mice: A Pilot Study
| العنوان: | Less Vertebral Bone Mass after Treatment with Macitentan in Mice: A Pilot Study |
|---|---|
| المؤلفون: | Liang Ming Zhang, Chunyi Wen, Chun Xiao Luo, Bin Liu, Limin Rong, Zhongyu Liu, Man Ting Au, Tian Wei He, Bu Yang |
| المصدر: | BioMed Research International BioMed Research International, Vol 2019 (2019) |
| بيانات النشر: | Hindawi, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Male, medicine.medical_specialty, Article Subject, medicine.medical_treatment, Intraperitoneal injection, Urology, lcsh:Medicine, 030209 endocrinology & metabolism, Pilot Projects, General Biochemistry, Genetics and Molecular Biology, Bone remodeling, 03 medical and health sciences, chemistry.chemical_compound, Mice, 0302 clinical medicine, Bone Density, medicine, Animals, Receptor, Vertebral bone, Macitentan, Mice, Inbred BALB C, Sulfonamides, Osteoblasts, General Immunology and Microbiology, Endothelin-1, business.industry, lcsh:R, Antagonist, General Medicine, Skeleton (computer programming), Spine, 030104 developmental biology, Pyrimidines, chemistry, Cancellous Bone, Hypertension, Immunohistochemistry, business, Research Article |
| الوصف: | Purpose. Blood vessels and skeleton interact together. Endothelin-1 is a potent vasoconstrictor and also has an effect on bone metabolism. The dual antagonist to both endothelin-1 type A and B receptors, Macitentan, has been approved for clinical management of pulmonary arterial hypertension while little is known about the secondary effect of the drug on spine. We aimed to answer how vertebral bone mass responded to Macitentan treatment in mice. Methods. Sixteen male balb/c mice at 6 months were randomly assigned into 2 groups. Vehicle and Macitentan were administrated via intraperitoneal injection to Control group and Treatment group, respectively, for 4 months. At sacrifice, plasma endothelin-1 was evaluated with ELISA and vertebral bone mass was evaluated with Microcomputed Tomography and histological analysis. Results. We found higher plasma endothelin-1 level (p Conclusions. Treatment with Macitentan is associated with significant lower vertebral bone mass and therefore the secondary effect of dual antagonists to endothelin-1 receptors on the skeleton should be monitored and investigated in clinical practice. Both osteoblasts and osteoclasts may be involved while the molecular mechanism needs to be further explored. |
| وصف الملف: | text/xhtml |
| اللغة: | English |
| تدمد: | 2314-6141 2314-6133 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db35a79baff14bc9716746cd53827edeTest http://europepmc.org/articles/PMC6399551Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....db35a79baff14bc9716746cd53827ede |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23146141 23146133 |
|---|